Scarica l'app Stockscreener
2.66
6.01%
-0.17
Dopo l'orario di chiusura:
2.49
-0.17
-6.39%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.83
Aprire:
$2.9
Volume 24 ore:
250.34K
Relative Volume:
2.08
Capitalizzazione di mercato:
$27.10M
Reddito:
$66.38M
Utile/perdita netta:
$-14.18M
Rapporto P/E:
-0.9475
EPS:
-2.8074
Flusso di cassa netto:
$-5.17M
1 W Prestazione:
+2.31%
1M Prestazione:
+18.75%
6M Prestazione:
+13.68%
1 anno Prestazione:
+49.44%
Intervallo 1D:
$2.595
$2.90
Intervallo di 1 settimana:
$2.56
$3.065
Portata 52W:
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Nome
Aytu Biopharma Inc
Settore
Telefono
(720) 437-6580
Indirizzo
7900 E. UNION AVENUE, DENVER
Confronta AYTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.66 | 28.83M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Iniziato | Lake Street | Buy |
| 2025-06-30 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Iniziato | H.C. Wainwright | Buy |
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
Buybacks Report: Is Aytu BioPharma Inc. stock dividend yield sustainableForecast Cut & Daily Volume Surge Signals - ulpravda.ru
Portfolio Recap: How sustainable is Aytu BioPharma Inc. stock dividend payoutQuarterly Market Summary & AI Enhanced Trading Alerts - ulpravda.ru
Why Aytu BioPharma Inc. stock attracts high net worth investorsMarket Risk Report & High Accuracy Trade Alerts - ulpravda.ru
Will Aytu BioPharma Inc. stock outperform tech sector in 2025July 2025 Sentiment & High Conviction Investment Ideas - ulpravda.ru
Why Aytu BioPharma Inc. stock is favored by top institutionsTreasury Yields & Comprehensive Market Scan Reports - ulpravda.ru
Entry Recap: Why Aytu BioPharma Inc. stock attracts high net worth investorsPortfolio Gains Summary & Weekly Top Stock Performers List - ulpravda.ru
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesLong-Term Investment Plans & Interactive Charts for Smarter Trading - ulpravda.ru
Aytu BioPharma (AYTU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Aytu BioPharma announces commercial availability of EXXUA tablets - MSN
Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber
How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India
Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria
Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada
Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World
Aytu BioScience Stockholders Approve Key Proposals - TipRanks
AYTU FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Ascendiant Capital raises Aytu Biosciences stock price target on Q1 beat - Investing.com Canada
AYTU Analyst Rating Update: Ascendiant Capital Raises Price Targ - GuruFocus
Revenue per share of Aytu BioPharma, Inc. – LSX:A3D38R - TradingView — Track All Markets
Will Aytu BioPharma Inc stock outperform Nasdaq index2025 Price Targets & Risk Controlled Daily Trade Plans - BỘ NỘI VỤ
How Low Can Aytu BioPharma Stock Really Go? - Trefis
Will Aytu BioPharma Inc. (AY20) stock profit from AI boom2025 Analyst Calls & Safe Entry Point Alerts - Newser
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulusJuly 2025 Patterns & Stock Portfolio Risk Management - Newser
How Aytu BioPharma Inc. (AY20) stock moves in volatile trading sessionsMarket Risk Report & Verified Technical Trade Signals - Newser
Is Aytu BioPharma Inc. (AY20) stock a fit for income portfoliosJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
Is Aytu BioPharma Inc. (AY20) stock resilient in recession scenariosJuly 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong - MSN
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - ACCESS Newswire
Aytu BioPharma (NASDAQ: AYTU) to Showcase at NobleCon21, Dec. 3 Presentation Webcast - Stock Titan
Aytu BioPharma Inc AY20 Stock Analysis and ForecastFundamental Strength Indicators & Superior Trading Strategies - earlytimes.in
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - MSN
Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance
Published on: 2025-11-21 03:45:24 - newser.com
Why Aytu BioPharma Inc. (AY20) stock is trending on social mediaOil Prices & Real-Time Stock Entry Alerts - newser.com
Published on: 2025-11-20 04:27:18 - newser.com
Is Aytu BioPharma Inc. stock cheap at current valuationJuly 2025 Selloffs & AI Driven Price Predictions - newser.com
What risks investors should watch in Aytu BioPharma Inc. stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.41%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):